echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The environmental analysis and experience of Japan's large health industry are used for reference

    The environmental analysis and experience of Japan's large health industry are used for reference

    • Last Update: 2021-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The large health industry is one of the largest in the world, with annual spending accounting for about 1/10 of the total GWP, and this proportion will continue to increase. Globally, Big Health is growing rapidly, with health-related stocks accounting for about 13% of the total market capitalisation. Large health industry will gradually become a strong new support for global economic development. To this end, the development of the great health industry in various countries to carry out a general view, easy to quickly look at the world's overall development of large health industry. This paper gives a brief overview of the development of Japan's large health industry., Japan's large health industry category definition research analysis
    Japan's large health industry is the collection of prevention, diagnosis, treatment, rehabilitation and other goods and services sector of the general term. This typically includes the pharmaceutical industry, the healthcare system, the health care industry, and social well-being.
    Japan's large health industry mainly includes three major areas: pharmaceutical industry, health care system, health care products. The pharmaceutical industry is divided into eight categories: pharmaceutical industry and pharmaceutical business, the health care system is divided into hospitals, clinics, insurance and social welfare provided by the State, and health care products are divided into specific health food and nutritional food.. Environmental Analysis of Japan's Great Health Industry
    The Japanese government vigorously promotes the healthy development of its citizens, strictly supervises food safety through legislation, attaches great importance to the construction of social welfare, and vigorously promotes the strategy of biological nation-building. At the same time, the population structure and social environment also form the basic industrial development environment.
    drug market in Japan is more standardized. Japan has a strict legal regime governing and regulating the drug market. The manufacture and sale of drugs have very strict regulations to ensure the safety and order of the drug market. Japan's drug regulatory laws and regulations fall into three main categories: called laws approved by the Japanese parliament, decrees or decrees approved by the Cabinet of Ministers of the Japanese Government, and notices or provincial decrees approved by the Minister of Health and Health. The laws on drug administration approved by the Japanese Parliament are the Pharmaceutical Act, the Pharmacist Act, etc. But the most important law for the drug market is the Pharmaceutical Act. Japan's pharmaceutical law to "pharmaceuticals", "pharmaceutical cosmetics", "cosmetics" and "medical appliances" and other four items, in order to ensure that the law regulating its safety and effectiveness, in the scope of pharmaceutical laws and regulations of goods, must abide by the provisions of the pharmaceutical laws, otherwise it is defined as a violation of the pharmaceutical laws.
    effect of the operation practice of the NHS is obvious. According to the regulations, Japanese nationals and foreigners who have lived in Japan for more than one year are required to join the National Health Insurance, pay a certain amount of insurance premiums and receive a National Health Insurance Certificate. Sick to the hospital, their own 30% of the medical expenses, the rest by the hospital and the local government where the patient settled. Japanese hospitals or clinics are subject to an insurance organization review before eligible people can provide medical insurance services. At present, there are nearly one million hospitals and clinics in Japan serving health care patients, and Japanese nationals can visit any of them with a health insurance card.
    to promote national health is an important task of the Japanese government. In the Ministry of Health and Labour, there is not only a health bureau, but also a special health promotion section, which is dedicated to the development and supervision of measures to improve the healthy life of the country. The Food Hygiene Act is an important regulation in the field of food in Japan. The main purpose of the Act is to prevent health hazards caused by diet and to protect the health of the people. The Health Energy Food System was introduced on April 1, 2001 and strictly restricts health food products. Japan has promulgated eight social welfare laws, known as the "Eight Laws on Social Welfare", which is the legal basis for the government to carry out social welfare administration and the basis for building a welfare society. The Government of Japan stressed the shift in the "focus of scientific research to life sciences and biotechnology" and formulated biotechnology strategies with the aim of building the competitiveness of the biotechnology industry.
    japan's good economic environment to promote the development of large-health industry. Japan's domestic economy is stable, with an average annual GDP growth rate of about 2.2%, creating a good environment for the development of the big health industry, but showing signs of market contraction; The yen has fallen since 2012, helping pharmaceutical exports.
    the accelerated aging of the population has a profound impact on the health industry. As of August 1, 2018, the proportion of people aged 70 and over in Japan's total population of 126 million was 20.7%, exceeding 20% for the first time. Statistics show that the number of people aged 70 and over increased by 1 million to 26.18 million, or 20.7% of the total population, while the number of people aged 65 and over defined as the elderly population increased by 440,000 over the previous year to 35.57 million, representing a new record of 28.1% of the total population. In addition, the number of people aged 80 and over in the elderly population increased by 310,000 over the previous year to 11.04 million (8.7 per cent of the total population); Japan's aging population is becoming increasingly serious. The rapid aging of Japan's population structure and the rigid growth of social security expenditure are one of the important factors to increase the financial burden. The Japanese people have a strong sense of health and pay attention to diseases caused by poor lifestyles. Japan's large health industry will increase demand for health products, medical services and medical supplies as the population ages.
    social and cultural environment. Residents attach great importance to raising health awareness, and it is common to spend money on health services. Many people regularly go to medical centers, receive medical guidance from doctors, and take the initiative to change their lifestyle. The diet is lighter.
    Japan is one of the most developed countries in the pharmaceutical, biotechnology and medical device industries. Japan is the world's second largest pharmaceutical market and is expected to continue to grow at a compound annual growth rate of 2.6%. Japan has unique advantages in fermentation engineering, biomedicine (especially genetic engineering and monoclonal anti-regime preparation), bio-environmental protection, bio-energy and other biotechnology industries. It has good prospects in drug discovery, biological services, medical devices and functional foods., experience learn from
    the Japanese people, the government, the community of health care, the strong awareness of the development of Japan's large health industry has been continuously improved and become the world's benchmark country.
    japan provides health care for all its citizens. Although Japan's medical expenses are not cheap, but there are few "difficult to see a doctor, expensive to see a doctor" phenomenon, Japanese nationals rarely because of economic reasons for the visit and did not see a doctor, the hospital did not stay in hospital, not only because the Japanese are richer than Chinese, but also because Japan provides medical security for the entire population, in addition to various types of supplementary insurance to share the remaining out-of-the-way medical expenses. Japan, like the United States, is the world's most developed commercial insurance industry, the competition between the insurance industry is relatively full, the management efficiency is relatively high. Many of the operations of Social Security are also carried out by these commercial insurance companies.
    reform of the tax and financial policy of the pharmaceutical industry. Japan's tax system consists of 57 taxes in three main categories: income tax, property tax and commodity tax. Taking into account the status of corporate body and the incentive effect of preferential tax policies in the pharmaceutical industry, Japan has given special tax benefits mainly from the aspect of corporate income tax. The preferential policy system mainly includes tax relief, tax deduction, accelerated depreciation, withdrawal of reserves and so on.
    establish a modern medical system and realize the division of medicine. By establishing a universally insured NHS, the chain of interests between doctors and drug suppliers has been cut off, drug prices have been set by the Government and profits of pharmaceutical manufacturing and operating enterprises have been protected to a certain degree. In Japan, doctors have become purely clinicians, and the main means of their medical income is to obtain the corresponding income by implementing a medical treatment and filling out a medical card. The measures taken by the Japanese Government to this end are actually very simple: to transfer doctors into the advanced technical services industry, greatly increase the remuneration of doctors for diagnosis and treatment. After a significant increase in the remuneration of doctors, the main source of income for doctors has changed from medicine to medicine. Doctors who are skilled and service-serative will be more likely to be booked by patients and have higher incomes. The doctor's income and social status have since been directly related to his medical skills. Encourage the establishment of private hospitals. As a result of the increase in life expectancy, the supply of beds in public hospitals was seriously inadequate, and a large number of social and private hospitals emerged after the 1970s, which provided a large number of beds, many of which were later converted into sanatorium hospitals. This is a way to adapt to the aging of health resources. One of the measures taken to establish geriatric hospitals in response to ageing is to encourage all sectors of society to establish geriatric hospitals dedicated to the elderly. The separation of convalesceive hospitalization from other types of hospitalization facilitates the centralized management of elderly chronically ill patients, thereby reducing medical costs.
    drug protection and support policies have effectively promoted the development of innovative drugs in Japan. Drug patent protection policies and drug data protection policies form a dual protection mechanism, especially for drugs that take a long time from development to approval. Unlike in Europe and the United States, Japan's drug protection system creatively bundles market access with a post-market review system, which helps to increase monitoring and control of adverse reactions to innovative drugs while protecting the intellectual property rights of innovative drugs. Intellectual property protection policy effectively curbs the "free ride" effect in the process of pharmaceutical technology innovation, and grants it market exclusive power after the market of innovative drugs, forms a market monopoly mechanism, prolongs the market life cycle of products, and guarantees the high profits of research and development enterprises.
    a unique and innovative drug regulation policy. Japan implements a unified national management of the government drug price management mechanism, its new drug pricing accounting model to adopt a "similar drug reference pricing method." That is, for the same adaptive disorder, the same efficacy, pharmacological effects and chemical structure of similar control drugs, combined with the innovative, practical and market-based factors of new drugs to determine drug prices. This policy effectively controls drug prices, lowers public health care costs, while giving innovative drug price increases the privilege, and vigorously promotes pharmaceutical companies to increase investment in research and development of innovative drugs, leading to the growth of pharmaceutical GDP. (Firestone Creation)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.